The main operational objective of diuretic therapy in patients who present congestive heart failure and hypertension is to reduce or to suppress excess bodily fluid. Effective diuretic therapy decreases cardiac size when the heart is dilated, and it reduces lung congestion and excess water. Consequently, external respiratory work diminishes and cardiac output would be redistributed in favour of systemic vascular beds other than that of the respiratory muscles; dyspnoea decreases markedly and there is a slight reduction in fatigue. This clinical improvement and the fall in body weight caused by diuretics entail an increase in effort capacity. Subsequent exercise training ameliorates the abnormal ventilatory response to physical effort and the skeletal muscle myopathy that occur in heart failure, and thereby it attenuates dyspnoea and decreases fatigue further. Loop and/or thiazide-type diuretics may be used to aug-
Introduction
Congestive heart failure (CHF) and hypertension coexist in many patients. Coronary artery disease, diabetes mellitus and/or renal insufficiency frequently accompany the CHF-hypertension association. Few investigative endeavours have addressed the effect of diuretic therapy in patients with CHF and hypertension specifically, despite the fact that diuretics are indicated for both conditions. Effective diuretic therapy is mandatory in patients with CHF, since no drug class other than diuretics can achieve what diuretics can in terms of control of excess bodily fluid and its attendant symptom mitigation. 
The clinical and functional effects of diuretics
Effective diuretic therapy provides impressive symptomatic relief in patients with CHF. [2] [3] [4] [5] Haemodynamically, forced diuresis results in a decrease in ment natriuresis in patients with congestive heart failure and hypertension. The state of renal function, the existence of certain co-morbid conditions, potential untoward drug actions, and possible interactions of diuretics with nutrients and with other drugs are some of the factors that must be considered at the time of deciding on the diuretic drug(s) and dose(s) to be prescribed. Spironolactone has been found to increase life expectancy and to reduce hospitalisation frequency when added to the conventional therapeutic regimen of patients with advanced congestive heart failure and systolic dysfunction. Therefore, spironolactone should be the drug of choice to oppose the kaliuretic effect of a loop or of a thiazide-type diuretic. Journal of Human Hypertension (2002) 16 (Suppl 1), S104-S113. DOI: 10.1038/sj/jhh/1001354 pulmonary circulation wedge pressure, and stroke volume and cardiac output decrease initially. Upon prolonged administration, the cardiac index may stay below, equal or surpass its pre-treatment value, but the magnitude of these changes is generally low. 7, 8 There is a lack of correlation between variables indicating effort capacity and cardiac output in patients suffering from chronic CHF, but we have found that the NYHA functional class 9 correlates positively and that the 6-min mean walking velocity 10 correlates negatively with clinical ( Figure 1 ) and radiological 11 increasing ordinal indicators of the magnitude of lung congestion and pulmonary water and with the cardiothoracic ratio. 12 These findings strongly suggest that the beneficial effects of diuretics on the main symptoms of CHF are mainly due to the decrease in thoracic fluid that results from their diuretic action. Thus, lung congestion and water and cardiac size should be considered operational objectives of diuretic therapy in CHF.
The substantial symptomatic relief produced by diuretics in patients with CHF is independent of whether patients also present hypertension. However, the blood pressure (BP) lowering effect of diuretics may result in improved cardiac pump Figure 1 The 6-min walking test was carried out and the pulmonary congestion-and-water clinical score was evaluated in 59 ambulatory patients who presented NYHA functional class I-IV congestive heart failure after 1 month of stable pharmacotherapy. Thirty-nine patients also suffered from essential hypertension. The pulmonary congestion-and-water clinical score, which has a possible range of 0-24, equals the sum of the scores assigned to eight symptoms and four signs that denote pulmonary congestion and excess water in congestive heart failure. Some dots comprise more than one patient each. From AJ Reyes, G Crippa, MG Meny, E Sverzellati, RD Espinas and M Giorgi-Pierfranceschi: unpublished study.
function and thus contribute to the clinical improvement when hypertension coexists. Reductions in dyspnoea, in systemic oedema and in BP have been found to progress in parallel over the first weeks of monopharmacotherapy with a diuretic in patients with CHF and hypertension. 13 The processes giving place to the two cardinal symptoms that limit physical activity in heart failure, namely dyspnoea and fatigue, 14, 15 have not been fully unveiled. 16 This paucity of information precludes that the mechanism(s) of the symptom attenuation brought about by forced diuresis in patients with CHF should be fully understood, mainly in view that diuretic therapy does not increase cardiac output to a great extent in most cases. We designed an hypothesis that focuses on the possible key role played by pulmonary congestion and water and by the respiratory muscles in this apparent paradox, 17, 18 and have been updating [19] [20] [21] our construct while considering progress in research and opinion. 22 Pulmonary circulation wedge pressure is increased in CHF. In consequence, there is a net passage of fluid from the pulmonary circulation to the lung interstitium and to the small airway. 23 Excess lung water and pulmonary circulation engorgement entail a decrease in pulmonary compliance and an increase in the airway resistance to air flow. 24 These two changes determine an increase in the work done by the respiratory muscles per respiratory cycle. The rise in volumes and pressures in the heart, in the pulmonary circulation and perhaps in intrathoracic lymphatics, the decrease in pulmonary compliance, and the underperfusion and structural, biochemical and functional deterioration that affects certain organs such as skeletal muscles, 25 including the respiratory muscles, originate stimuli that increase (effort) ventilation inordinately in patients with CHF. Therefore, respiratory work per cycle and respiratory rate rise strikingly and quickly
Journal of Human Hypertension upon exercise. Patients perceive these intense and/or rapid increases in respiratory work per minute as dyspnoea. 26 Elevations in respiratory work per minute imply that a high fraction of cardiac output should be addressed to the muscles of the external respiration, to the detriment of the fraction that perfuses other systemic vascular beds. This added underperfusion that affects the muscles of the limbs during physical effort is an immediate determinant of fatigue. 27 Resting and exercise local underperfusion and the systemic functional shifts that occur in CHF would account for the muscle waste and for the microanatomical, biochemical and functional unfavourable changes undergone by skeletal muscle in CHF. These changes would constitute the basis of the development of fatigue when physical activity augments relative underperfusion.
When treatment of chronic CHF with a diuretic is effective, ie when it increases diuresis to the sought extent, pulmonary wedge pressure and lung water decrease, 28 and therefore respiratory work per minute decreases. Cardiac output would undergo a redistribution whereby a lower fraction is addressed to the respiratory muscles, which might be better perfused than before the institution of diuretic therapy despite this reduction, and more blood would reach other systemic regions, including the muscles of the limbs. Additionally, cardiomegaly subsides, and body weight decreases. These favourable changes result in an important reduction in dyspnoea and in a small decrease in fatigue, and therefore in an increase in the capacity to perform physical activity. 27 In the medium range, increased physical activity, particularly if it includes exercise training, would improve the structure and function of skeletal muscle [29] [30] [31] [32] [33] and would reduce excess ventilation, [33] [34] [35] [36] thereby mitigating dyspnoea and fatigue further.
Diuretics provide the prime relief of the symp-
Modern diuretics
Modern diuretics augment natriuresis by blocking the reabsorption of sodium from the microtubular structures of the kidney. In normal circumstances, about 65, 25, 8 and 2% of filtered sodium is reabsorbed in the proximal convoluted tubule, in the thick ascending limb of the loop of Henle, in the early distal tubule, and in the connecting tubule and the cortical collecting duct, respectively. The clinical pharmacology of modern diuretics has been reviewed recently.
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Early distal tubular (thiazide-type) diuretics
Early distal tubular diuretics comprehend the thiazides, which are benzothiadiazine derivatives, and a set of other compounds that includes chlorthalidone, chlorexolone, cicletanine, clopamide, indapamide, metolazone, and xipamide. Cicletanine is the only thiazide-type diuretic in use that is not a sulfonamide drug. Early distal tubular diuretics reach the nephronal tubular lumen through the cells of the proximal tubule, and act on the cells of the early distal tubule from the tubular fluid. There, these diuretics interfere with the reabsorption of sodium chloride and thus increase natriuresis. 38 The elevations in tubular fluid flow and sodium concentration that result from the blockade of sodium reabsorption in the early distal tubule give place to an increase in the reabsorption of sodium in the connecting tubule and the collecting duct. At this level, reabsorbed sodium is exchanged for potassium and hydrogen, and kaliuresis rises in consequence.
Early distal tubular diuretics are efficacious antihypertensives. Indapamide and cicletanine lower high BP effectively, but the actions of these diuretics in patients with CHF remain largely unexplored.
Loop diuretics
Loop diuretics (furosemide, bumetanide, ethacrynic acid, piretanide and torasemide) reach the lumen of the nephron at the proximal tubule, and they increase natriuresis by interfering with the reabsorption of filtered sodium in the thick ascending limb of the loop of Henle. 39 Part of the sodium whose reabsorption is impeded in the loop of Henle is reabsorbed in the early distal tubule and in later tubular structures. The natriuretic response to loop diuretics is accompanied by an elevation in kaliuresis.
The effect of loop diuretics on renal sodium excretion increases as a function of the dose over a wider dose range than the natriuresis that occurs in response to the other diuretic classes, and the renal excretory response to loop diuretics is quicker than the responses to the diuretics of any other class.
Furosemide, bumetanide and piretanide have an ancillary site of renal action in the proximal tubule of the nephron, where they inhibit carbonic anhydrase. Ethacrynic acid and torasemide do not exert a significant action on the proximal tubule. Torasemide reduces high BP effectively when it is used as oral monopharmacotherapy in patients with essential hypertension.
Potassium-retaining diuretics
Potassium-retaining diuretics have their site of renal action in the connecting tubule and in the adjacent cortical collecting duct, 40 ie at the level where sodium is reabsorbed from the tubular lumen and potassium and hydrogen are excreted in exchange. This physiological process is stimulated by aldosterone. The potassium-retaining diuretics amiloride and triamterene increase natriuresis by blocking a sodium channel involved in the exchange of this cation for potassium and hydrogen. 9 Spironolactone and potassium canrenoate compete with aldosterone for the intracellular receptor of this hormone in the tubular cells.
Potassium-retaining diuretics increase natriuresis and cause renal retention of potassium and of hydrogen ions through the decrease in sodium reabsorption that they provoke. Antikaliuretics increase natriuresis modestly and they may provoke hyperkalaemia. For this reason, potassium-retaining diuretics are generally co-prescribed with a thiazidetype or with a loop diuretic.
New use of spironolactone in congestive heart failure
The anti-aldosterone substance spironolactone is currently classified as a facultative diuretic and antikaliuretic, 41, 42 since it increases natriuresis and decreases kaliuresis only when plasma aldosterone concentration is high, as occurs when sodium intake is low or when loop or thiazide-type diuretics are used at diuretic doses. 43 Spironolactone has been classically used in patients with CHF treated with loop or with early distal tubular diuretics mainly to prevent or to co-treat hypokalaemia. Recently, it was found that the addition of a relatively small dose of spironolactone to the classic treatment of CHF with a loop or a thiazide-type diuretic, digitalis and an angiotensin-converting enzyme (ACE) inhibitor prolongs life and reduces hospitalisation frequency in patients with advanced cardiac failure and systolic dysfunction. 44 It is not known whether this salutary action of spironolactone is due to a decrease in the rate at which cardiac interstitial fibrosis progresses, 45, 46 to an improvement in bodily potassium turnover, to added natriuresis, or to a combination of factors. The addition of a low amount of spironolactone to antihypertensive treatment with conven-tional doses of diuretics may result in a supplementary fall in high BP. 47 The fact that spironolactone could oppose aldosterone-induced processes that could favour cardiac fibrosis in patients with CHF makes this drug the second diuretic of choice in three circumstances that may apply to patients with CHF and hypertension, provided it is not contraindicated: first, when it is decided to increase the natriuretic response to ongoing therapy with a thiazide-type or a loop substance by adding a diuretic of a different class to the therapeutic regimen; second, when it is decided to prevent the development of hypokalaemia by using an antikaliuretic; third, when a slight increase in the antihypertensive action of existing diuretic therapy is sought.
Spironolactone should be used with caution, since its additive natriuretic effect in cases who also receive a loop or a thiazide-type diuretic may facilitate the development of hyponatraemia. Furthermore, hyperkalaemia may develop when renal function is impaired or when spironolactone is coadministered with potassium supplements, and also when it is co-administered with an ACE inhibitor or an angiotensin II receptor blocker. 48 Spironolactone provokes renal retention of hydrogen ions; therefore, it should not be used in patients with metabolic acidosis and it should be used with great care in patients who are prone to develop this syndrome (eg patients who also present insulin-dependent diabetes mellitus).
Use of diuretics in the clinical setting
The principal operational objective of diuretic therapy in patients with CHF and hypertension is to rid the lungs of excess fluid to the maximal extent compatible with a safe general haemodynamic response. In patients who also present serious renal insufficiency, the increase in BP is usually determined by excess fluid; consequently, lowering high BP constitutes an important additional operational objective of diuretic therapy in these cases.
General principles
All the subtleties of good clinical handling should be brought about to individualise treatment with diuretics in patients who present CHF and hypertension. The existence of other syndromes or diseases that may be relevant to diuretic therapy either per se (eg renal insufficiency) or because of the medication necessary to treat them (eg chronic rheumatic diseases) should be taken into account. Due attention should be paid to the interactions between diuretics and the other drugs used for heart failure and eventually for hypertension. Some general principles should be observed with respect to the handling of diuretics. These drugs must be used at diuretic doses, ie at doses higher than those used to treat uncomplicated essential hypertension. HowJournal of Human Hypertension ever, the doses of diuretics should be kept below those that produce very quick and/or intense diuresis, to avoid symptomatic and asymptomatic pathophysiologically detrimental falls in cardiac output. If BP is not controlled, co-treatment with other drug classes that are established antihypertensives and are used in CHF in addition to diuretics, such as ACE inhibitors, must be adjusted. Other antihypertensive agents should be added if necessary.
The amount of sodium in the diet should be optimised. A diet containing 70-90 mmol of sodium daily should be prescribed to patients with mild or moderate cardiac failure who do not present renal insufficiency and are not co-treated with spironolactone. Lower intakes activate the renin-angiotensinaldosterone (RAA) System and thereby increase kaliuresis and result in added cardiovascular damage; higher intakes increase the amount of filtered sodium that reaches the sodium-potassium exchange site in the kidney and thus increase kaliuresis, and they require that higher doses of diuretics should be used. Water intake should be decreased when thiazide-type diuretics are used, to decrease the risk of hyponatraemia.
Initial treatment and maintenance therapy
Treatment may be initiated with a thiazide-type diuretic in patients who present CHF and hypertension and normal renal function. Once-daily oral doses of 5 mg bendrofluazide, 50 mg chlorthalidone, 5 mg clopamide, 0.5 mg cyclopenthiazide, 25-50 mg hydrochlorothiazide, 5-10 mg metolazone and 20 mg xipamide are appropriate starting doses in most cases. In patients with mild CHF, these amounts of early distal tubular diuretics may be effective when taken every other day.
The usefulness of thiazide-type agents notwithstanding, loop diuretics are generally preferred as first-line agents given that they have an ampler doseresponse range than early distal tubular drugs. Additionally, loop diuretics are safer than thiazidetype substances with respect to the reductions in the serum concentrations of sodium (particularly when patients are also treated with spironolactone) and potassium that may accompany any given natriuretic effect. When renal function is seriously impaired, thiazide-type drugs per se are ineffectual whereas loop diuretics preserve their capacity for increasing natriuresis. Treatment with loop diuretics may be started with daily oral doses of 40 mg furosemide, 1 mg bumetanide, 6 mg piretanide or 10 mg torasemide.
Spironolactone should be co-prescribed in patients with advanced heart failure and systolic dysfunction in whom it is not contraindicated. The starting dose should be 12.5 mg once daily. Eventually this amount may be doubled in patients who present normal renal function, no hyperkalaemia and no hyponatraemia and who tolerate spironolactone clinically.
The dose of the diuretic and the amount of excess bodily fluid are two important determinants of the response of diuresis. When treatment is effective, 24-h diuresis increases markedly over the first 1-4 days, it declines over the following 7-20 days, and it stabilises thereafter. The new external sodium balance is sensitive to various factors, including sodium intake, the intensity of diuretic therapy, cardiac function and renal function. 49 The dose of the diuretic(s) should be adjusted as necessary in the course of treatment, according to changes in the external sodium balance that might be necessary to maintain 'dry lungs', and to control hypertension in patients with advanced renal insufficiency.
Monitoring efficacy and safety
The response to diuretic therapy should be monitored adequately. Efficacy evaluation should focus on the presentations of congestion and excess water in the lungs and in the rest of the thorax. 1 Other efficacy variables to be considered include urinary output, body weight, the possible systemic clinical presentations of excess bodily fluid and the response of BP.
The state of the lungs should always be evaluated through careful anamnesis on effort dyspnoea, orthopnoea and paroxysmal nocturnal dyspnoea, and on effort and supine coughing and wheezing. Auscultation of the lungs, preferably done immediately after nocturnal bed rest, is also important. Good quality chest X-rays are very useful since they show pleural effusion when it exists, and they may reveal pulmonary congestion and/or imbibition by showing upper vein distention, peribronchial cuffing, poor vessel margination, Kerley's lines, thickened interlobar fissures and/or perihiliar haze. 50 Chest X-rays also permit to evaluate the cardiothoracic ratio.
The clinical evaluation of systemic peripheral oedema should focus on the lumbosacral region in patients who keep bed rest, and on the existence of hand oedema immediately after wakening and of ankle-pedal-region oedema in the evening in ambulatory patients. Neck vein distention, the presence of excess fluid in the abdominal region (hepatomegaly, ascites) and the hepato-jugular reflex should always be searched for.
Instrumental and laboratory safety evaluations should include, at least, frequent ECG recordings and assessments of blood sugar and of the serum concentrations of creatinine, sodium, potassium, calcium, magnesium and uric acid.
Diuretic pseudoresistance and resistance
Diuretic therapy with a relatively high dose of a loop diuretic, eg 160 mg furosemide daily, may fail to produce the desired reduction in excess bodily fluid in patients without important renal function impairment. Most frequently this is due to low compliance with treatment, to excess sodium intake, or to the effect of co-medications that cause renal retention of sodium. The latter include agents for heart failure, such as vasodilators, or for other conditions (eg nonsteroidal anti-inflammatory drugs, corticosteroids). In other instances, the prevailing mechanism conducing to failure of loop diuretic therapy to control excess bodily fluid is significant true resistance of the nephron to the action of loop diuretics. 51 True resistance to a loop diuretic may be solved by augmenting the dose in some circumstances. However, very high doses many times fail to produce an adequate therapeutic response, 51 and they convey an increased risk of loop diuretic ototoxicity. We do not usually surpass total oral daily doses of 160 mg furosemide, 4 mg bumetanide or 60 mg torasemide when renal function is not seriously impaired. In case these doses are not effective, we implement the time-honoured manoeuvre of blocking sodium reabsorption in different sites of the tubular structure of the kidney. Sequential blockade of sodium reabsorption, by co-administration of a loop diuretic and a thiazide-type drug and/or a potassium-retaining substance, generally results in the desired increase in natriuresis. In cases with significant renal insufficiency, the doses of loop diuretics may be higher, and the sequential blockade of sodium reabsorption should usually be limited to these drugs and thiazide-type substances. If natriuresis does not increase to the sought extent, it is necessary to recur to dialysis.
Unwanted actions of diuretics
Possible untoward actions of diuretics stem from their dose-dependent pharmacological actions or constitute idiosyncratic reactions. The most frequent and important pharmacologically originated undesirable effects of diuretics in patients with CHF and hypertension consist in neuroendocrine activation, in unfavourable changes in sodium, potassium, calcium and magnesium turnovers, in an untoward shift in carbohydrate metabolism and in hyperuricaemia. Potassium-retaining diuretics may affect acid-base balance untowardly in acidosisprone patients.
Neuroendocrine activation
Diuretics increase the activity of the RAA System, mainly through their action on the kidney, in patients with heart failure. 52, 53 This activation has various functional and structural negative implications for patients with CHF and hypertension; therefore it should be prophylactically minimised by prescribing a diet containing an optimal amount of sodium and by using the minimal dose of diuretic that is effective. The raised activity of the RAA System may be attenuated or countered by the use of drugs such as ACE inhibitors, angiotensin II antagonists and spironolactone. Intravenous furosemide has been found to augment plasma arginine vasopressin, apparently by a non-osmotic mechanism. 54 This shift may have deleterious effects on vascular function and may contribute to the development of hyponatraemia.
Hyponatraemia
The capacity of the kidney to dilute urine, ie to excrete water, is impaired in CHF. The processes underlying this functional change are poorly understood. The increased sympathetic activity that occurs in CHF, and perhaps the rises in angiotensin II, natriuretic peptides and some endothelins and prostaglandins that also take place in this syndrome, augment the osmotic-independent production and release of arginine vasopressin and thus result in elevated reabsorption of water from the renal tubular system and favour the development of hyponatraemia. 55 Exaggerate restrictions of sodium intake and water or hypotonic fluid intake in response to thirst caused by increased sodium and water losses, eg when sweating is intense, may conduce to hyponatraemia in patients with CHF treated with diuretics.
The natriuretic action of diuretics may eventuate in the development of hyponatraemia in patients with CHF. 56 Hyponatraemia is most usually caused by thiazide-type diuretics and by their fixed-dose combinations with a potassium-retaining agent. 48 Women, the elderly and patients with advanced CHF are at higher risk of developing diureticinduced hyponatraemia.
The simplest measure aimed at lowering the risk of hyponatraemia consists in reducing water intake.
Hypokalaemia
Loop and thiazide-type diuretics increase kaliuresis in dose-dependent fashion and thus tend to lower serum potassium concentration. 57 The sodium-channel blockers amiloride and triamterene and the aldosterone antagonist spironolactone, when co-prescribed at adequate doses, significantly attenuate or blunt the increase in kaliuresis produced by loop and early distal tubular diuretics. 57 ACE inhibitors and angiotensin II receptor antagonists tend to elevate serum potassium concentration.
Hypokalaemia provokes skeletal muscle weakness, which may express itself as an increase in fatigue, and it favours the occurrence of cardiac arrhythmias.
The correction of hypokalaemia conveys the reversal of nearly all the derangements it causes. However, reversing the increase in cardiac arrhythmogenicity requires that body magnesium depletion, which accompanies hypokalaemia in many instances, should also be corrected. Potassium replacement 58 is the most effective therapy for hypo-
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kalaemia. Spironolactone and amiloride may contribute to the correction of low serum potassium, but the added natriuretic effect of these potassiumretaining diuretics favours the development of hyponatraemia and co-dministration of potassium supplements and a potassium-retaining drug may result in hyperkalaemia.
Hyperkalaemia
Hyperkalaemia elevates aldosterone production, and it may cause cardiac death. Renal insufficiency predisposes to the development of and may cause hyperkalaemia. Potassium supplements may increase serum potassium concentration to undesirable levels. Potassium-retaining diuretics, ACE inhibitors, angiotensin-II receptor blockers, non-steroidal antiinflammatory drugs and many other agents 59, 60 may cause or facilitate the development of hyperkalaemia, mainly when they are co-prescribed with potassium supplements.
Hypocalcaemia and hypercalcaemia
Loop diuretics increase renal calcium excretion and thereby tend to lower the serum concentration of calcium. 61 These agents should not be used, unless they are indispensable, in CHF patients who present hypocalcaemia or who are predisposed to the formation of renal calcium stones.
Early distal tubular diuretics cause renal retention of calcium; 61 therefore these substances should not be used in patients who present hypercalcaemia. Thiazide-type diuretics are the agents of choice in patients with CHF who are prone to renal calciumstone formation, since they appear to prevent calcium urolithiasis through their action on the renal handling of calcium. 62 Amiloride decreases calciuresis, 63 attenuates the calciuretic effect of loop diuretics 64 and augments the calcium-retaining effect of the thiazides. 65 When dealing with hypocalcaemia in patients treated with diuretics, it must be taken into account that it may be due to magnesium deficiency.
66,67
Magnesium depletion
Loop and early distal tubular diuretics increase magnesiuresis. [67] [68] [69] Amiloride and spironolactone tend to cause mild renal retention of magnesium, and they attenuate or counter the excess magnesiuresis caused by loop and by thiazide-type diuretics. 67, 68 The magnesiuretic action of common diuretics may result in bodily magnesium depletion in patients who present CHF. 70, 71 Magnesium depletion is more likely to develop in certain patients, including those who also suffer from diabetes, alcoholics, heart transplant recipients treated with the immunosuppressant cyclosporin, and individuals whose magnesium intake is poor. 66, [70] [71] [72] Magnesium depletion frequently accompanies hypokalaemia in patients treated with diuretics, and it gives place to hypocalcaemia. 66, 67 The likelihood of occurrence of cardiac arrhythmias in patients who present hypokalaemia or who are treated with digitalis is enhanced by magnesium depletion. 73 Magnesium depletion in patients with CHF who receive a loop or a thiazide-type diuretic should be treated with magnesium supplements.
70,71
Changes in carbohydrate metabolism
Treatments with loop or with early distal tubular diuretics reduce glucose tolerance and may provoke hyperglycaemia. 74 In patients who present diabetes mellitus, diuretics usually increase blood sugar and glycosylated haemoglobin. The mechanism of this seemingly unavoidable effect of diuretics on carbohydrate metabolism, which appears to be facilitated by hypokalaemia and perhaps by magnesium depletion, is not well understood. Diuretics have been found to decrease insulin secretion and to cause resistance to insulin, but none of these changes is a constant feature of diuretic-induced glucose intolerance. 75 Diuretics may also contribute to the development of the hyperosmolar non-ketotic syndrome in diabetic patients. 76 Potassium-retaining diuretics should be used with great care in cases who present insulin-dependent diabetes mellitus, given that these patients are prone to develop metabolic acidosis and that these drugs reduce the renal excretion of hydrogen ions and thereby tend to lower plasma pH.
Hyperuricaemia
The prevalence of hyperuricaemia is high in patients suffering from hypertension and in patients who present CHF. Hyperuricaemia, which appears to be an independent cardiovascular risk factor 77 and is a marker of poor prognosis in patients with heart failure, 78, 79 may have deleterious effects on the kidney and on the urinary tract. 80, 81 Progressive degrees of renal insufficiency give place to progressively higher values of serum uric acid concentration. When renal function is unimpaired, a decrease in the renal excretion of urate originating in the tubular nephron is an important determinant of hyperuricaemia in patients with CHF and/or hypertension. 82, 83 Sodium intake curtailment reduces the renal excretion of urate and favours the development of diuretic-induced hyperuricaemia.
Diuretics constitute the main causative factor of hyperuricaemia in patients with CHF. 80 Diuretics in use reduce the renal excretion of urate and increase the serum concentration of uric acid in dose-dependent fashion, 84, 85 apparently by shifting the balance of the secretion-reabsorption process undergone by uric acid in the nephronal proximal tubule towards reabsorption. The thiazide-type diuretic tienilic acid (ticrynafen), which is not available in most countries, increases the renal excretion of uric acid. 86 The early distal tubular diuretic cicletanine does not affect the renal output of urate 87 and does not elevate serum uric acid concentration 88 at the doses used to treat hypertension; the possible use of cicletanine in patients with CHF remains to be investigated.
Diuretic-induced increases in serum uric acid may be attenuated or countered by ACE inhibitors, 89, 90 since these substances increase the renal excretion of urate. 64, [91] [92] [93] [94] Serum uric acid concentration usually decreases after an ACE inhibitor is added to the therapeutic regimen in patients with CHF who present diuretic-induced hyperuricaemia; this makes it possible to reduce the dose or to discontinue the use of allopurinol in many patients who receive this drug to lower the production of uric acid. The angiotensin II receptor antagonist losartan has been found to increase the renal excretion of urate in healthy subjects, 95 and both losartan and irbesartan have been found to attenuate hydrochlorothiazide-induced increases in serum uric acid in hypertensive patients. 96, 97 Changes in acid-base balance Potassium-retaining diuretics cause renal retention of hydrogen ions and thereby tend to provoke acidosis, 48 particularly in patients at risk such as individuals who present renal insufficiency, subjects who also suffer from insulin-dependent diabetes and elderly persons.
Loop and thiazide-type diuretics generally cause sustained hypokalaemic-hopochloraemic alkalosis, which is usually mild and does not require treatment. 98 However, these substances do not lower urine pH to an appreciable extent. This is so because common diuretics exert pharmacological actions that result in opposite changes with respect to the renal excretion of hydrogen ions. Common diuretics block the reabsorption of filtered sodium in their main site of renal action, and part of the non-reabsorbed sodium is reabsorbed in exchange for potassium and for hydrogen ions, which are excreted, in the collecting duct. Thus, hydrogen ions excretion tends to increase and urine pH tends to decrease. However, the renal excretion of hydrogen ions tends to decrease as a result of the inhibition of carbonic anhydrase that most loop and thiazide-type substances cause in the proximal tubule.
The loop diuretic torasemide, at variance with furosemide, bumetanide and piretanide and with thiazide-type diuretics, does not act on the proximal tubule of the nephron; 99, 100 in consequence, torasemide decreases urine pH significantly at the doses used to treat CHF (AJ Reyes and WP Leary, unpublished results). Hence torasemide should be the loop diuretic of choice in patients who are at natural risk of developing acidosis or who are co-treated with a potassium-retaining diuretic.
Change in renal function
Diuretic therapy with thiazide-type and/or loop diuretics at the doses used in patients with CHF usually results in a small decrease in creatinine clearance.
Topics for future research
The possible advent of certain new drug classes (eg, neutral endopeptidase inhibitors, antagonists of the V2 receptor of arginine vasopressin) may have an important impact in the manner in which diuretics are being used in patients who present CHF and hypertension.
